Selected article for: "cytokine storm and present study"
Author: Nas, Kemal; Eryilmaz, Nuran; Geyik, Mehmet Faruk; AltaÅŸ, Ayfer
Title: COVID-19 in patients with familial Mediterranean fever treated with colchicine: case based review
  • Cord-id: 7r37zjep
  • Document date: 2021_2_21
    • ID: 7r37zjep
    Snippet: Coronavirus disease 2019 (COVID-19) refers to the clinical picture of an important and severe infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Considering the current knowledge on the pathophysiology and clinical manifestations of COVID-19, it is safe to state that both COVID-19 and inflammatory rheumatic disorders cause a cytokine storm and merit treatment with anti-rheumatic drugs. Three patients, who were on regular follow-up due to the diagnosis of f
    Document: Coronavirus disease 2019 (COVID-19) refers to the clinical picture of an important and severe infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Considering the current knowledge on the pathophysiology and clinical manifestations of COVID-19, it is safe to state that both COVID-19 and inflammatory rheumatic disorders cause a cytokine storm and merit treatment with anti-rheumatic drugs. Three patients, who were on regular follow-up due to the diagnosis of familial Mediterranean fever (FMF), contracted COVID-19 infection; and their pre-clinical and post-clinical data as well as laboratory, prognosis and treatment data were investigated. Effects of colchicine in FMF patients who contracted COVID-19 infection were presented in this study. All the cases recovered from COVID-19 without complications. The present study suggests that colchicine can positively affect the prognosis of COVID-19 in FMF patients; therefore, experience of rheumatologists in the use of anti-inflammatory drugs can be highly instrumental in management of COVID-19 patients.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and additional disease: 1
    • abdominal pain and additional risk: 1, 2, 3, 4
    • abdominal pain and additional symptom: 1, 2
    • abdominal pain and loading dose: 1, 2
    • abdominal pain and long term efficacy: 1
    • abdominal pain and long term therapy: 1, 2, 3, 4
    • abdominal pain and loss appetite: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
    • abdominal pain and lung infiltration: 1
    • abdominal pain and lung injury: 1, 2, 3, 4, 5
    • actin cytoskeleton and acute ards respiratory distress syndrome: 1
    • acute ards respiratory distress syndrome and additional disease: 1
    • acute ards respiratory distress syndrome and additional risk: 1, 2, 3, 4, 5, 6
    • acute ards respiratory distress syndrome and administer therapy: 1, 2
    • acute ards respiratory distress syndrome and loading dose: 1
    • acute ards respiratory distress syndrome and long term therapy: 1